Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial

References

• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al, for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9: 105–116.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP pus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH 03-2B): an open-label randomised phase 3 trial. Lancet 2011;378:1858–1867.
   PubMed Web of Science ®Google Scholar
• Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013;14:525–533.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Jung S-H, Porcu P, et al. A Cancer and leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012;97:758–765.
   PubMed Web of Science ®Google Scholar
• Tarella C, Zanni M, Di Nicola M, et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous haematopoietic stem cell support:a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007;21:1802–1811.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Chiappella A, Angelucci E, et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica 2009;94:1250–1258.
   PubMed Web of Science ®Google Scholar
• Dilhuydy M-S, Lamy T, Foussard C, et al. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large B-cell lymphoma: final analysis of a phase II GOELAMS study. Biol Blood Marrow Transplant 2010;16: 672–677.
   PubMed Web of Science ®Google Scholar
• Fitoussi O, Belhadj K, Mounier N, et al. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica 2011;96:1136–1143.
   PubMed Web of Science ®Google Scholar
• Milpied N-J, Leouill S, Lamy T, et al. No benefit of first-line rituximab (R) - high-dose therapy (R-HDT) over R-CHOP14 for young adults with diffuse large B-cell lymphoma. Preliminary results of the GOELAMS 075 prospective multicentre randomized trial. Blood 2010;116:(suppl. 1): Abstract 685.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Chiapella A, Brusamolino E, et al. Randomized multicentre phase III study for first line treatment of young patients with high risk (aaIPI 2-3) diffuse large B-cell lymphoma (DLBCL): rituximab (R) plus dose-dense chemotherapy CHOP14/MegaCHOP14 with or without intensified high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Results of DLCL04 trial of Italian Lymphoma Foundation (FIL). Ann Oncol 2011;22:(suppl. 4): Abstract 072.
   Google Scholar
• Schmitz N, Nickelsen M, Ziepert M, et al.; German High-Grade Lymphoma Study Group (DSHNHL). Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012;13:1250–1259.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Tarella C, Gianni AM, et al. Chemoimmunotherapy with R-CHOP or high dose sequential therapy (R-HDS) with autologous stem cell transplantation (ASCT) for high risk DLBCL patients: preliminary results of the randomized RHDS0305 trial by Gruppo Italiano Terapie Inovative nei Linfomi (GITIL). Hematol Oncol 2013;31:(suppl. 1): Abstract 120.
   Google Scholar
• Stiff PJ, Unger JM, Cook R, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 2013;369:1681–1690.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851–862.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002;87:1258–1264.
   PubMed Web of Science ®Google Scholar
• Rieger M, Ossterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011;22:664–670.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma 2009;9:381–385.
   PubMedGoogle Scholar
• Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:1408–1416.
   PubMed Web of Science ®Google Scholar
• Pytlik R, Kubackova K, Kozak T, et al. Favorable outcome of high-risk mediastinal diffuse large B-cell lymphoma (DLBCL) after dose-intensive chemotherapy, rituximab and autologous transplant (ASCT). Blood 2004;104:(suppl. 1): Abstract 1322.
   Google Scholar
• Pytlik R, Belada D, Kubackova K, et al. Intensive induction is beneficial for high risk younger patients with aggressive B-cell lymphoma, while frontline ASCT brings no benefit: final analysis of MegaCHOP-BEAM and MegaCHOP-ESHAP-BEAM studies. Blood 2007;108:(suppl. 1): Abstract 4692.
   Google Scholar
• Stoppa AM, Bouabdallah R, Chabannon C, et al. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1997;15:1722–1729.
   PubMed Web of Science ®Google Scholar
• Trneny M, Pytlik R, Belada D, et al. Treatment of diffuse large B-cell lymphoma with rituximab, intensive induction and high-dose consolidation: the final analysis of the Czech Lymphoma Study Group (CLSG) R-MegaCHOP-ESHAP-BEAM (R-MEB) Trial. Blood 2007:110:(suppl. 1): Abstract 21.
   Google Scholar
• Abou-Elella AA, Weisenburger DD, Vose JM, et al. Primary mediastinal large B-cell lymphoma:a clinicopathologic study of 43 patients from The Nebraska Lymphoma Study Group. J Clin Oncol 1999;17:784–790.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244–1253.
   Web of Science ®Google Scholar
• Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006;17:123–130.
   PubMed Web of Science ®Google Scholar
• Zhu YJ, Huang JJ, Xia Y, et al. Primary mediastinal large B-cell lymphoma (PMLBCL) in chinese patients:clinical characteristics and prognostis factors. Int J Hematol 2011;94:178–184.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 2012;17:239–249.
   PubMed Web of Science ®Google Scholar
• Soumerai JD, Hellmann MD, Feng Y, et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease.
   Google Scholar
• Tai WM, Quah D, Yap SP, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients. Leuk Lymphoma 2011;52:604–612.
   PubMed Web of Science ®Google Scholar
• Xu LM, Fang H, Wang WH, et al. Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy. Leuk Lymphoma 2013;1684–1690.
   PubMed Web of Science ®Google Scholar
• Klapper W, Kreuz M, Kohler CW, et al. Patient age at diagnosis is associated with the molecular characteristics of the diffuse large B cell lymphoma. Blood 2012;119:1882–1887.
   PubMed Web of Science ®Google Scholar